Cas:1005785-85-2 5-(2-Methyl-2-propanyl)-2-pyridinecarboxylic acid manufacturer & supplier

Chemical Name:5-(2-Methyl-2-propanyl)-2-pyridinecarboxylic acid

CAS.NO:1005785-85-2

Synonyms:4-tert-butyl-2-picolinic acid;2-Pyridinecarboxylic acid, 5-(1,1-dimethylethyl)-;5-(2-Methyl-2-propanyl)-2-pyridinecarboxylic acid;5-TERT-BUTYLPICOLINIC ACID;5-TERBUTYLPIEOLINIC ACID

Molecular Formula:C₁₀H₁₃NO₂

Molecular Weight:179.216

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:306.1±30.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.526

PSA:50.19000

Exact Mass:179.094635

LogP:1.59

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-tert-butyl-2-picolinic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-TERBUTYLPIEOLINIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-tert-butyl-2-picolinic acid Use and application,2-Pyridinecarboxylic acid, 5-(1,1-dimethylethyl)- technical grade,usp/ep/jp grade.

Related News: The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. 5-(2-Methyl-2-propanyl)-2-pyridinecarboxylic acid manufacturer China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition. 5-(2-Methyl-2-propanyl)-2-pyridinecarboxylic acid supplier Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations. 5-(2-Methyl-2-propanyl)-2-pyridinecarboxylic acid vendor Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed. 5-(2-Methyl-2-propanyl)-2-pyridinecarboxylic acid factory The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.